Novel PDE4 Inhibitor Slows IPF Progression

(MedPage Today) -- Novel oral agent nerandomilast slowed progression of idiopathic pulmonary fibrosis (IPF), even atop background antifibrotic therapy, the phase III FIBRONEER-IPF trial showed.
Forced vital capacity (FVC) declined from baseline...